125 results about "Renal damage" patented technology

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and / or P-gp only inhibitors.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

The invention provides a combined lactobacillus salivarius YS-UR90 and a preparation method of the combined lactobacillus salivarius YS-UR90. The saliva combined lactobacillus provided by the invention can secrete protease and glycosidase, and the HCT and FLS gene expression levels of the saliva combined lactobacillus are high, so that the saliva combined lactobacillus can promote phenolic acid active ingredients to generate biotransformation during fermentation, and the proportion of chlorogenic acid and the like in fermentation liquor is increased. For example, marine fish oligopeptide and casein phosphopeptides are used as a composite nitrogen source, dandelion powder is used as a functional substrate, and a composite fermentation product obtained through fermentation of saliva and lactobacillus has the effect of promoting uric acid excretion and has a certain protection effect on kidney injury. The compound fermentation product has the effect of improving hyperuricemia mainly by inhibiting XOD activity, increasing serum urea nitrogen level, improving defect expression of uric acid synthesis gene HPRT1, inhibiting expression of uric acid reabsorption URAT1 and GLUT9 genes and improving expression of excretion genes OAT1 and ABCG2.

The invention discloses a marine fish uric acid lowering peptide with kidney protection activity as well as a preparation method and application of the marine fish uric acid lowering peptide. The marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, with kidney protection activity is prepared, and the marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, can remarkably reduce the blood uric acid level in a body, promote uric acid excretion and improve pathological damage of the kidney. In addition, the pentapeptide provided by the invention can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury, and has a good application prospect.

An Akk11 strain-containing probiotic agent capable of relieving hyperuricemia, and the use thereof. Strains in the probiotic agent include an Akkermansia muciniphila Akk11 strain and a Lactobacillus johnsonii LJ09 strain. It is found in the present application that the two strains possess a potential interaction and can cooperate with each other, thereby synergizing the effect of relieving hyperuricemia, which is specifically manifested in: being capable of remarkably regulating uric acid metabolism and improving renal clearance functions; being capable of effectively inhibiting the activity of a key enzyme for uric acid synthesis so as to reduce the production of uric acid, and being capable of remarkably relieving renal damage and renal dysfunctions associated with high levels of uric acid.

Described herein is a method for mixing unequal amounts of two reagents to produce a detectable reaction in a microfluidic chip. In one example, there is a fluorescent microfluidic urinary albumin chip (UAL-Chip) that exploits the nonimmunological fluorescent assay. In this chip, we constructed a passive and continuous mixing module, in which the loading process requires only an inexpensive dropper, and the signal is stable over time, as discussed below. We applied a pressure-balancing strategy based on the immiscible oil coverage which highly improves the precision in controlling the mixing ratio of sample and dye. The UAL-Chip has achieved an estimated limit of detection (LOD) of 8.4 μg / ml using albumin standards, which is below the 30 μg albumin per ml urine level considered to be indicative of kidney damage.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition and its use for preventing or treating hyperuricemia. The technical problem to be solved by the present invention is to provide a new option for treating hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for preventing or treating hyperuricemia, comprising the following ingredients: thistle, gardenia, bamboo leaves, angelica, lily, corn silk, broccoli seed extract, and eucommia leaves. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, improving kidney damage, and protecting the liver.

The invention belongs to the technical field of biological medicine, and particularly relates to application of macrophage LSR gene and / or LSR protein in preparation of drugs and diagnostic products for preventing and / or treating diabetic nephropathy. Research finds that the LSR deletion of macrophages aggravates renal injury by promoting inflammatory response of diabetic nephropathy and increasing lipid renal toxicity; on the contrary, after the LSR expression of the macrophages is recovered, the inflammatory response and lipid droplet deposition of the kidney of the diabetic nephropathy mouse can be effectively reduced, and meanwhile, the kidney injury is improved. Cell experiments show that LSR deletion of macrophages can activate a YAP signal channel to increase secretion of inflammatory factors and reduce low-density lipoprotein uptake at the same time. Therefore, the macrophage LSR can be used as a diabetic nephropathy drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention discloses a preparation method of an astragalus extract with a uric acid reducing effect, and belongs to the technical field of biological medicines. The method comprises the following steps: concentrating an ethanol extract of radix astragali, extracting by using n-butyl alcohol, ethyl acetate and petroleum ether respectively, and concentrating an extract to obtain n-butyl alcohol, ethyl acetate and petroleum ether extraction parts and residual parts respectively, so as to obtain an n-butyl alcohol extract, namely the radix astragali extract for reducing uric acid. Efficacy experiments show that the normal butanol extraction part of the ethanol extract of the astragalus membranaceus can obviously reduce the serum uric acid level (SUA) of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) and effectively improve kidney injury caused by the hyperuricemia. The uric acid reducing effect of the radix astragali n-butyl alcohol extract is close to that of a clinical drug allopurinol, and the radix astragali n-butyl alcohol extract has wide development and application prospects in the aspect of relieving hyperuricemia.

The present invention provides a polysaccharide that has a protective effect on kidney damage. The polysaccharide of the present invention is obtained from the receptacle of Podocarpus carylus or Podocarpus brevifolia, plants of the Podocarpaceae family, after ultrasonic extraction, distilled water reheating extraction, reduced pressure concentration, ethanol precipitation, and freeze-drying. According to content determination, the mass percentage of the polysaccharide of the present invention is greater than or equal to 50% in terms of glucose. The polysaccharide is composed of 7 monosaccharides, including mannose, rhamnose, glucose, galactose, xylose, arabinose and L-fucose. In vivo experiments on mice have confirmed that the polysaccharide of the present invention has a good protective effect on kidney damage caused by cisplatin. The polysaccharide of the present invention can be used to prepare medicines with a protective effect on kidney damage.

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating hyperuricemia, renal damage and fibrosis, and its application. The technical problem to be solved by the present invention is to provide a new option for the treatment of hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for treating hyperuricemia, renal damage and fibrosis, comprising the following ingredients: mistletoe, phellodendron, oriental water chestnut, ginseng, astragalus, polygonatum, lotus leaf, cirsium japonicum and panax notoginseng. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, and improving renal damage, and can be used to treat hyperuricemia without causing liver damage.

The invention provides application of FXR protein as a target spot in preparation of a medicine for relieving and / or treating renal toxicity of tacrolimus, and belongs to the technical field of biological medicine. The invention proves that the activity or expression level of the FXR protein is regulated in a targeted manner, so that the Tacrolimus-induced renal tubule epithelial cell vacuolation and renal tubule injury can be effectively prevented or relieved, and the abnormal rise of early renal injury markers such as urine NAG enzyme and the like is reduced, thereby directly improving the renal toxicity problem of Tacrolimus. The invention provides a new drug action target and a treatment strategy for clinic, and by developing an FXR agonist or a gene intervention means, the long-term renal injury risk of tacrolimus can be reduced while the anti-rejection curative effect is maintained, the transplanted kidney function and the survival time of a patient are prolonged, and the clinical application prospect is wide. And an effective means is provided for solving the unsatisfied clinical demand of the renal toxicity of the tacrolimus after the transplantation operation.

The present invention relates to a composition for preventing, alleviating or treating metabolic diseases, the composition comprising a rosuvastatin and ursodeoxycholic acid conjugate or a pharmaceutically acceptable salt thereof, in which the statin conjugates to an ursodeoxycholic acid transporter and has the effects of function inhibition, cholesterol level reduction, antilipid toxicity, body weight reduction, blood lipid reduction, fatty liver alleviation, inflammation alleviation, and kidney damage alleviation. The composition, in the form of a single formulation, has the characteristics of maintaining the therapeutic effects of rosuvastatin and ursodeoxycholic acid while reducing the side effects of existing statins, and thus can be widely used as a substitute for complex formulations in the treatment of metabolic diseases.

The application discloses a lactobacillus johnsonii OD-5 and application and products thereof, and belongs to the technical field of microorganisms. A technical problem to be solved by the application is to provide a lactobacillus johnsonii capable of treating kidney stones. A technical solution is a lactobacillus johnsonii OD-5 with a preservation number of CGMCC No. 38426. The lactobacillus johnsonii can reduce urine oxalic acid and regulate urine calcium, effectively correct abnormal urine biochemical conditions promoting stone formation, reduce related kidney function damage, and inhibit formation and deposition of calcium oxalate crystals in the kidney at a histopathological level, thereby significantly reducing the stone incidence. The application provides a solid theoretical basis for development of products taking the lactobacillus johnsonii OD-5 as a core component and used for preventing kidney stones and improving stone kidney damage.

The invention relates to a specifically degraded KIM1 liposome, preparation thereof and application of the specifically degraded KIM1 liposome in preparation of medicines for treating kidney diseases, and belongs to the technical field of biological medicines. According to the invention, a KIM1 targeting polypeptide and an E3 ubiquitin ligase ligand (such as lenalidomide) are respectively modified on the surface of a liposome. The lipidosome capable of specifically degrading the KIM1 can be rapidly enriched in a damaged kidney after renal injury occurs, and the KIM1 protein level in the damaged kidney is degraded by 75%. Meanwhile, the druggability problems of poor solubility, low bioavailability and the like caused by large molecular weight of the compound in the PROTAC drug development process are avoided, and the technical problems that drugs are difficult to prepare and kidney injury drugs are lacked in the prior art are solved.

The application discloses application of Dingxuan Granules in preparation of medicines for treating early kidney damage caused by hypertension of the type of yin deficiency and yang hyperactivity, and the Dingxuan Granules are prepared from radix rehmanniae, lycium barbarum, gastrodia, uncaria, wine salvia miltiorrhiza, alisma, motherwort and achyranthes bidentata. The Dingxuan Granules have the effects of tonifying liver and kidney, calming liver wind and promoting water and descending qi, and are suitable for people with early kidney damage caused by hypertension.

The present invention relates to dihydroquinazolinone compound, a preparation method therefor, and a use thereof. The dihydroquinazolinone compound has an excellent inhibitory effect on GLUT9, can effectively inhibit GLUT9 activity so as to promote uric acid excretion, thereby achieving a uric acid lowering effect, and can be used for treating diseases related to GLUT9 activity or expression. The dihydroquinazolinone compound or a pharmaceutically acceptable salt thereof has no obvious toxicity to organs, can significantly reduce kidney damage caused by hyperuricemia, and alleviates gout symptoms.

This invention discloses a traditional Chinese medicine composition for the prevention and / or treatment of type 2 cardiorenal syndrome and its application. By weight, the raw materials of the traditional Chinese medicine composition include: Astragalus membranaceus 15-30 parts, Paeonia lactiflora 10-20 parts, Saposhnikovia divaricata 5-10 parts, Leonurus japonicus 9-30 parts, Massa fermentata 9-30 parts, Poria cocos 10-30 parts, Cinnamomum cassia twig 9-30 parts, Atractylodes macrocephala 10-30 parts, and Glycyrrhiza uralensis 2-10 parts. This traditional Chinese medicine composition is mainly targeted at patients with early-stage renal damage in type 2 cardiorenal syndrome due to spleen-yang deficiency and blood stasis obstructing the collaterals. It utilizes a combination of various traditional Chinese medicines, whose active ingredients synergistically enhance each other, thereby achieving the therapeutic effect of improving early-stage renal damage after chronic heart failure and delaying the pathological progression of type 2 cardiorenal syndrome.

The invention belongs to the technical field of biological medicines, and discloses an application of clematis total saponins in preparation of medicines for treating acute gouty arthritis and improving uric acid renal injury, which is characterized in that dried roots or rhizomes of clematis northeast of a clematis plant of ranunculaceae are crushed to extract the clematis total saponins; the extracted radix clematidis total saponins can reduce the uric acid level while relieving the symptoms of acute gouty arthritis, effectively relieve renal injury caused by high uric acid level, and have potential application in treating acute gouty arthritis and improving uric acid renal injury.

The present invention discloses the use of salinomycin in the preparation of a medicament for reducing uric acid and / or treating hyperuricemia. In addition, the present invention also claims the use of salinomycin in the preparation of a medicament for treating and / or preventing gout or gout complications caused by hyperuricemia, and the use of salinomycin in the preparation of a medicament for treating renal damage caused by hyperuricemia. The salinomycin can effectively reduce uric acid in the serum of an animal, can play a role in treating hyperuricemia, can play a role in alleviating renal damage, and has no obvious side effects.

Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.

The invention belongs to the technical field of medicines, and particularly relates to application of a small molecule regulator to improvement of AKI treatment by promoting EPC cell differentiation. In order to develop a new AKI treatment scheme, the research finds that the Orticumab can promote EPC cell differentiation (not only can enhance cell viability and up-regulate an anti-inflammatory factor IL-10, but also can down-regulate proinflammatory factors TNF-alpha, IL-1beta and IL-6), so that kidney tissue damage after mouse renal ischemia reperfusion is effectively relieved, renal function deterioration is relieved, and inflammatory response is inhibited. The application shows that the Orticumab can improve the renal ischemia reperfusion injury by promoting the differentiation of EPC cells so as to play a role in protecting the renal I / R injury, and the discovery provides a new therapeutic scheme for improving AKI.

This invention relates to the application of Y27632 in the preparation of drugs that promote the repair and / or regeneration of kidney injury, and pertains to the field of pharmaceutical technology. The application of Y27632 in the preparation of drugs that promote the repair and / or regeneration of kidney injury. This invention demonstrates for the first time the significant effect of Y27632 in promoting the repair and regeneration of acute kidney injury in mice, providing strong experimental evidence for the development of novel drugs for the repair and / or regeneration of kidney injury. This invention provides a new and effective means of treating kidney injury, such as acute kidney injury, by using the ROCK signaling pathway inhibitor Y27632. Experiments of this invention confirm that Y27632 can effectively promote the repair and regeneration of kidney injury by inhibiting the ROCK signaling pathway, upregulating SOX-9 expression, activating the endogenous repair mechanism of the kidney, reducing the expression of damage markers, alleviating kidney pathological damage, relieving renal fibrosis, and salvaging kidney function. This has significant clinical application value and broad market prospects.

The invention discloses an application and a preparation method of a marine fish protein peptide with effects of reducing uric acid and protecting kidneys. The marine fish protein peptide VK with uric acid reduction and kidney protection activity is prepared, and the marine fish protein peptide VK can remarkably reduce the blood uric acid level in the body and improve pathological injury of the kidney. Furthermore, the preparation process is further optimized, and the content of the dipeptide VK in the zymolyte is increased. The preparation method provided by the invention is simple in process, realizes enzymolysis controlled release of the target polypeptide, and can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury.

The invention relates to the technical field of biological medicine, and particularly discloses a platelet membrane-coated mitochondrial compound and a preparation method and application thereof, and the platelet membrane-coated mitochondrial compound comprises mitochondria extracted from mammalian tissues and a platelet membrane coating the outer layer of the mitochondria. According to the present invention, the high kidney injury targeting enrichment rate is achieved through the PMITO compound constructed by coating the mitochondria with the platelet membrane, the healthy mitochondria is accurately delivered to the focus, and the energy crisis and the cell apoptosis are directly reversed; meanwhile, the biomimetic membrane structure can actively adsorb key inflammatory factors such as TNF-alpha and IL-1beta to synergistically realize dual mechanisms of energy repair and inflammation regulation, so that renal function indexes are remarkably improved in an animal model, and tissue pathological damage is relieved; finally, a new strategy for treating the renal ischemia-reperfusion injury, which is high in targeting property, clear in curative effect and good in biological safety, is formed.

The invention provides application of inhibiting expression of split protein in uranium-induced renal injury repair and treatment targets, the split protein comprises Drp1 and Fis1, and by inhibiting expression of the split protein Drp1 and Fis1, the concentration of glutathione and SOD enzyme activity after uranium-induced renal injury are improved, the concentration of malondialdehyde after uranium-induced renal injury is reduced, and the uranium-induced renal injury repair effect is improved. And the oxidative stress reaction caused by uranium can be recovered.